Molecular genetic studies in epithelial cells of lung cancer and COPD patients by Boelens, Mirjam Catharina
  
 University of Groningen
Molecular genetic studies in epithelial cells of lung cancer and COPD patients
Boelens, Mirjam Catharina
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Boelens, M. C. (2008). Molecular genetic studies in epithelial cells of lung cancer and COPD patients. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the







GENERAL INTRoDUC TIoN 1

Lung cancer
Lung cancer is the leading cause of cancer mortality worldwide and is for over 90% 
caused by smoking. In the Netherlands, lung cancer was diagnosed in 9,014 patients (6,126 
males, 2,888 females) in 2003 and almost the same number of patients (6,480 males and 
2,855 females) died of lung cancer in 2004 (www.rivm.nl)1. The most recent data from 
Statistics Netherlands show a further increase with 9,426 patients dying from lung cancer 
in 2006 (www.cbs.nl). The staging system for lung cancer is based on the TNM (Tumor, 
Node, Metastasis)-classification, as summarized in Table 12. This classification provides 
information on the tumor load and spread, and is used as a measure for prognosis and 
treatment. Based on the TNM status, lung cancer is subdivided into discernable stages, 
ranging from stage IA (early stage) to stage IV (advanced stage) (Table 2)3. In general, higher 
stages correlate with worse survival outcomes. At the time of diagnosis most lung cancer 
patients have already developed distant metastases (stage IV). It is important to look for 
metastases during staging of the patient, since metastases, rather than the primary tumors 
are responsible for most lung cancer deaths. Lung cancer often metastasizes via the lymphatic 
system to regional lymph nodes and/or hematologically to distant organs (mainly to bone, 
brains, liver and adrenal glands). The 5-year overall survival for lung cancer patients is 
strongly dependent on the tumor stage, decreasing from 65-70% for stage IA to 1-2% for 
stage IV with an average 5-year survival of about 10-15%3,4. 
Lung cancer can be subdivided into small cell lung cancer (SCLC) (15%) and non-
small lung cancer (NSCLC) (85%) based on the global histological characteristics of the 
tumor cells. SCLC grows and metastasizes rapidly and tends to arise in the larger airways. 
While SCLC is initially more sensitive to chemotherapy, patients have a worse prognosis 
due to chemo resistance at tumor relapse and due to the high frequency of metastases 
at presentation. This type of lung cancer is in almost all cases associated with smoking5. 
NSCLC encompasses several distinct subtypes including the most common squamous cell 
(SCC) and adenocarcinoma (AC) subtypes. The SCC subtype is also strongly associated 
Figure 1. Transformation from normal bronchial epithelium to SCC6. Hyperplasia and squamous metaplasia may transform 
back to normal epithelium when the patient quits smoking. The next transformation steps are first mild dysplasia and then 
moderate to severe dysplasia and carcinoma in situ. The latter stages are considered to be irreversible steps towards malignancy 












with smoking, whereas the AC subtype is also observed in non-smokers. The bronchial 
epithelial cell is considered to be the precursor cell of SCC6. As a result of smoking, normal 
bronchial epithelium can transform into metaplastic squamous epithelial cells that may 
become dysplastic. Advanced dysplasia is considered to be a premalignant stage for SCC 
(Figure 1). AC is suggested to originate from bronchial glandular epithelial cells or the 
surrounding stem cells. SCC used to be the most common histological subtype (40%), but 
recently a shift has been observed towards the AC subtype (Figure 2)1,7,8.
The choice of treatment in patients with NSCLC does not only depend on the stage 
of the disease but also on comorbidity and the condition of the patient. For early stage 
NSCLC, surgery with adjuvant chemotherapy is the most effective approach. Generally, one 
or more lobes are removed from the lung (lobectomy or pneumectomy), together with the 
draining lymph nodes. When the primary tumor can not be removed completely, or when 
dissemination of the primary tumor cells has been identified, combination therapy will be 
given (Table 1).
Tumor stage (T)
T1 Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic 
evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)
T2 Tumor with any of the following features of size or extent: More than 3 cm in greatest dimension; 
Involves main bronchus, 2 cm or more distal to the carina; Invades the visceral pleura; Associated with 
atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire 
lung
T3 Tumor of any size that directly invades any of the following: chest wall (including superior sulcus 
tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 
2 cm distal to the carina, but without involvement of the carina; or associated atelectasis or obstructive 
pneumonitis of the entire lung
T4 Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, 
esophagus, vertebral body, carina; or tumor with a malignant pleural or pericardial effusion, or with 
satellite tumor nodule(s) within the ipsilateral primary tumor lobe of the lung
Lymph Node stage (N)
N0 No regional lymph node metastasis
N1 Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes 
involved by direct extention of the primary tumor
N2 Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or 
supraclavicular lymph node(s)
Distant Metastasis stage (M)
M0 No distant metastasis
M1 Distant metastasis present
Table 1. TNM classification for lung cancer
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Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity 
and mortality worldwide. The major risk factor for the development of COPD is tobacco 
smoke, which accounts for 80-90% of the COPD cases. Genetic factors, such as α1-antitrypsin 
deficiency, present in about 1-5% of the COPD population, influences the susceptibility to 
COPD9. However, many other genetic factors may contribute to the development of COPD. 
In the Netherlands, COPD is diagnosed in about 33,000 patients (17,200 males, 16,400 
Table 2. Tumor staging and treatment
Stage TNM stage Treatment
IA T1 N0 M0 surgery
IB T2 N0 M0 surgery + adjuvant chemotherapy
IIA T1 N1 M0 surgery + adjuvant chemotherapy
IIB T2 N1 M0, T3 N0 M0 surgery + adjuvant chemotherapy
IIIA T3 N1 M0 surgery + adjuvant chemotherapy
T1-3 N2 M0 combination chemo-radiotherapy
IIIB T1-4 N3 M0, T4 N0-2 M0 combination chemo-radiotherapy

























































































































Figure 2. Age-standardized incidence of lung cancer in the Netherlands according to sex and histological subtype 
(1989-2003), for male (A) and female (B). The presence of SCC decreases through the years in males, while in females AC is an 




females) in 2003 and 5,662 patients (3,381 males, 2,281 females) died of COPD in 2004 
(www.rivm.nl). COPD is an irreversible chronic airway disease characterized by persistent 
and irreversible airway obstruction. The diagnosis COPD is made – as defined by the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) – by spirometry when the 
postbronchodilator Forced Expiratory Volume in one second/Forced Vital Capacity (FEV1/
FVC) ratio is below 70%. COPD can be classified in different GOLD stages of severity based 
on FEV1% predicted (Table 3)10. 
Depending on the disease severity, COPD is treated with bronchodilator/anti-
inflammatory medications (anticholinergics, sympaticomimetics and inhaled or 
systemic corticosteroids), supplemental oxygen or surgery (lung volume reduction or 
lung transplantation). In very advanced disease, i.e. patients with GOLD stage IV, lung 
transplantation is the only alternative to increase life expectancy.
COPD includes two main disease manifestations, chronic bronchitis/bronchiolitis, with 
obstruction in large and small airways, and emphysema with destruction of alveolar walls 
and enlargement of airspaces. Most COPD patients have a combination of both chronic 
bronchitis/bronchiolitis and emphysema. The airflow limitation is usually progressive 
and associated with an abnormal chronic reaction of the lungs, such as inflammation, 
oxidative stress and tissue remodeling, due to the toxic smoking particles11. Pathologic 
changes underlying the clinical symptoms of COPD can be found in the large and small 
airways, and in lung parenchyma. In the airways, inflammatory cells are recruited to 
the subepithelial layer and these cells can infiltrate also in the surface epithelium12,13. In 
addition, chronic inflammation can lead to ongoing cycles of injury and repair (remodeling) 
of the airway wall and hyperplasia of goblet cells and mucus glands in the airways results 
in mucus hypersecretion14. Destruction of the lung parenchyma in patients with smoking-
Table 3. GOLD classification of severity of COPD
GOLD stage FEV1
I: Mild COPD FEV1 ≥ 80% predicted
II: Moderate COPD  50% ≤ FEV1 < 80% predicted
III: Severe COPD 30% ≤ FEV1 < 50% predicted
IV: Very Severe COPD
FEV1 < 30% predicted, or FEV1 < 50% 
predicted plus chronic respiratory failure
FEV1, forced expiratory volume in one second
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induced COPD typically occurs as centrilobular emphysema. This involves dilatation and 
destruction of the peribronchial alveolar attachments15. 
Smoking, lung cancer and COPD
In 2006, about 28% of the Dutch population smoked (31% male and 25% female) with 
an average of 15 cigarettes per day (www.stivoro.nl). Almost 20,000 people died in 2005 
as a consequence of smoking. Smoking increases the risk of lung cancer (relative risk of 
7.9-29.3) and COPD (relative risk of 2.3-13.7). About 90% of the patients with lung cancer 
and/or COPD have a long smoking history16,17. Despite the clear link with smoking, only 
15-20% of the cigarette smokers develop lung cancer and/or COPD which suggests that 
other risk factors contribute to the susceptibility of these diseases and to their differential 
development18,19. Independent of the smoking history, COPD itself is also a risk factor for 
the development of lung cancer. Several epidemiological studies showed that the relative 
risk for developing lung cancer increases from at least 2-fold with moderate COPD to 10-
fold with severe COPD20-27. Furthermore, COPD seems to be especially a risk factor for the 
SCC subtype21. 
Cigarette smoke is a complex heterogeneous mixture containing more than 5,000 
chemical compounds among which carbon oxide, nitric oxide, free radicals, and tar 
(aromatic hydrocarbons containing nicotine, hydroquinones, catechols and several 
Figure 3. Smoking 
can activate bronchial 
epithelial cells to excrete 
chemokines, free radicals 
and proteases. This may 
lead to CoPD-related 
processes such as 
inflammation (neutrophils, 
macrophages, CD8+ T-


















carcinogens)28. There is sufficient evidence based on animal studies and humans cell lines 
that over 60 components present in cigarette smoke have a carcinogenic potential29.
The airways are covered with a layer of epithelial cells. These epithelial cells are the first 
line of defense against inhaled toxic substances, such as cigarette smoke and air pollution. 
This subsequently leads to a variety of signals to adjacent cell types in the bronchial wall. 
Bronchial epithelial cells are considered to give rise to the SCC subtype6. 
In COPD, the airway epithelial cells can produce various chemokines that contribute 
to the recruitment of inflammatory cells, leading to the initiation of a local inflammatory 
process and fibrosis, which are the main pathogenetic processes in the airways of patients 
with COPD30-32 (Figure 3). The bronchial epithelium of COPD patients often shows squamous 
metaplasia, which is the result of chronic irritation, in case of COPD by the combination 
of cigarette smoke and inflammation. Proliferation of basal epithelial cells is increased in 
some healthy smokers, but is markedly increased in patients with COPD33.
Molecular genetic studies in epithelial cells of lung cancer and COPD patients
Microarray technology
Microarray is a frequently used technique to screen genome-wide changes/alterations at 
the RNA or DNA level in a wide variety of tissue samples or cells originating from all kind 
of species (Figure 4). Since its first application in the mid 1990s34, microarray technology 
has been successfully applied to almost every aspect of biomedical research35-40. Microarrays 
can be used to study chromosomal alterations41 using array based comparative genomic 
hybridization (array-CGH) and to study gene expression changes in cell types of interest in 
relation to specific characteristics. 
Laser dissection microscopy (LDM) is a recently developed technique that allows 
analysis of specific cell types from complex tissue samples. It has become an important tool 
to isolate pure cell populations from heterogeneous tissue42. In combination with the more 
recently developed DNA and RNA amplification procedures, analysis of LDM samples 
using microarray technology has been implemented in many studies43-50.
Comparative genomic hybridization (CGH) studies in NSCLC
Specific chromosomal aberrations have been found in many subtypes of cancers. In solid 
tumor these aberrations usually are copy number changes (gains or losses) of chromosomes. 
A gain or loss of genomic DNA may result in a change in expression levels of genes that are 
located on the altered chromosomal regions. Such a region may harbor an oncogene that 
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represents a driver gene on which these NSCLC tumors remain dependent with respect 
to their proliferation and survival, a phenomenon called “oncogene addiction”. Moreover, 
a loss of tumor suppressor genes may play an important role in the ultimate biological 
behavior of the tumor. During the development of cancer, copy number changes at specific 
chromosomal regions occur. Over the past years many techniques have been developed and 
applied to characterize specific chromosomal aberrations (LOH, FISH) or to identify these 
aberrations in a genome wide approach (multi color FISH, MLPA, CGH, aCGH, SNP array). 
Based on the accurate mapping data of the oligo’s / BACs on the arrays, the aCGH technique 
presents a powerful tool to identify the candidate target genes in genomic regions with copy 
number aberrations. In NSCLC, several common chromosomal copy number changes have 
been described, i.e. gains of 3q, 5p, 7q, 8q, 11q and 16p, and losses of 3p, 4q, 5q, 6q, 8p, 9p, 
13q and 17q as reviewed by Balsara et al.51.
Gene expression studies in bronchial epithelium and NSCLC
A pitfall of gene expression profiling studies is the large number of probes on the array 
(many thousands) in relation to the relative limited number of samples (usually less than 
100). This unbalance between the number of genes and the number of samples lowers the 







Figure 4. The principle of the microarray technology is based on simultaneous hybridization of a fluorescently labeled test 
(Cy3) and reference sample (Cy5) (either RNA or DNA) on a microarray slide containing thousands of oligonucleotide, cDNA or 
BAC probes. The intensity of the signals for both Cy3 and Cy5 are translated to gene expression or copy number changes of single 




for robust statistical analyses including multiple testing correction and validation of the 
results at RNA and/or protein level to extract the relevant differences. More and more tools 
are becoming available to extract significant differences related to specific pathways, gene 
ontologies and chromosomal regions. Moreover, microarray studies are frequently used to 
generate new hypotheses which can be the subject of new studies. 
Gene expression profiling in normal bronchial epithelium requires the use of airway 
brushes or laser microdissection of lung tissue in order to enrich pure bronchial epithelial 
cells. Most published studies so far have used brush-derived epithelial samples for 
microarray studies and investigated smoke-related52-54 gene expression profiles. Many genes 
with significant changes in expression levels were observed in normal bronchial epithelial 
cells from smokers and non-smokers; these genes were mainly related to oxidative stress 
responses. After smoking cessation of at least two years, the altered expression levels for 
most of these genes returned back to the levels of a non-smoker52. In relation to COPD, one 
study analyzed oxidative stress related genes and observed that part of these genes were 
upregulated in COPD patients as compared to healthy smokers54. Other genes or proteins 
that have been described as differentially expressed between epithelium of patients with 
and without COPD include growth factors and their receptors and adhesion molecules55-
57. Gene expression profiling in brush-derived normal epithelial cells from patients with 
and without lung cancer resulted in a subset of 80 genes that may serve as a lung cancer 
biomarker prediction set58. 
In NSCLC, several studies identified a specific gene expression profiles that could 
discriminate between or was related to specific histological subtypes of NSCLC59-61. 
Other studies have focused on the relationship of gene expression profiles with clinical 
characteristics this resulted in specific gene expression signatures in relation to time of 
survival59,62-64, chemosensitivity65,66, or lymph node metastasis65,67,68. Furthermore, many 
studies contributed to an enhanced pathogenetic understanding in cellular processes 
involved in oncogenesis of NSCLC among which apoptosis and cell-cycle progression69-74. 
With respect to smoking, it is observed that NSCLC developed in smokers have a different 
gene expression profile than NSCLC developed in never-smokers, indicating that smoking 
leads to a different pathogenesis of NSCLC75-77.
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Scope of the thesis
The aim of this thesis is to explore potential smoking- and/or COPD-related gene 
expression signatures in histologically normal bronchus epithelium and in SCC. We started 
with a pilot experiment to test the feasibility of using routinely collected tissue from normal 
bronchial wall, SCC and AC (chapter 2). As a next step, we tested the laser dissection 
microscopy (LDM) approach to allow isolation of pure normal bronchial epithelium and 
pure SCC tumor cells in combination with gene expression arrays. To examine the extent of 
the experimental bias due to amplification procedures required to gain sufficient RNA from 
LDM samples we compared the expression profiles from single and double amplification 
rounds (chapter 3). After these two studies, we collected a number of normal bronchial 
epithelial and SCC tissue samples from patients in such a way that these patients were 
matched for their smoking history (smoking status and packyears), COPD status and 
presentation of lymph node or distant metastasis. This enabled us to investigate whole 
genome gene expression in normal bronchial epithelium and in SCC and copy number 
changes in SCC in relation to these features (Figure 5). In chapter 4, we investigated the 
smoking related effects in normal bronchial epithelium and SCC by comparing expression 
profiles of current and ex-smokers. The genes that showed a marked smoking-induced effect 
in normal bronchial epithelium were also analyzed in SCC. In chapter 5, we investigated 
whether a difference exists between gene expression signatures in patients with and without 
COPD in both normal bronchial epithelium and SCC. In chapter 6, we compared genome-
wide DNA copy number alterations in primary SCC in relation to metastatic behavior.
Figure 5. Smoking is a risk factor 
for the development of CoPD and 
lung cancer. CoPD is independent 
of smoking behavior also a risk 
factor for the development of 
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